Genetic depletion of Polo‐like kinase 1 leads to embryonic lethality due to mitotic aberrancies

Citations Over TimeTop 21% of 2016 papers

Abstract

Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays multiple and essential roles during the cell division cycle. Its inhibition in cultured cells leads to severe mitotic aberrancies and cell death. Whereas previous reports suggested that Plk1 depletion in mice leads to a non-mitotic arrest in early embryos, we show here that the bi-allelic Plk1 depletion in mice certainly results in embryonic lethality due to extensive mitotic aberrations at the morula stage, including multi- and mono-polar spindles, impaired chromosome segregation and cytokinesis failure. In addition, the conditional depletion of Plk1 during mid-gestation leads also to severe mitotic aberrancies. Our data also confirms that Plk1 is completely dispensable for mitotic entry in vivo. On the other hand, Plk1 haploinsufficient mice are viable, and Plk1-heterozygous fibroblasts do not harbor any cell cycle alterations. Plk1 is overexpressed in many human tumors, suggesting a therapeutic benefit of inhibiting Plk1, and specific small-molecule inhibitors for this kinase are now being evaluated in clinical trials. Therefore, the different Plk1 mouse models here presented are a valuable tool to reexamine the relevance of the mitotic kinase Plk1 during mammalian development and animal physiology.

Related Papers

• → Progress in the Discovery of Polo-like Kinase Inhibitors(2005)111 cited
• → Inhibitors of the Polo‐Box Domain of Polo‐Like Kinase 1(2015)26 cited
• → A review of Plks: Thinking outside the (polo) box(2022)20 cited
• Preclinical Research and Early Clinical Research of Polo-like Kinase 1 Inhibitors(2011)
• A Molecular Docking Study of Aristolactam Analogues against Polo-Box Domain (PBD) of Human Polo Like kinase-1 in Cancer Progression(2014)